Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study

Mahyar Etminan PharmD MSc, Farzin Forooghian MD MSc, David Maberley MD MSc

Background: There have been several published reports of inflammatory ocular adverse events, mainly uveitis and scleritis, among patients taking oral bisphosphonates. We examined the risk of these adverse events in a pharmacoepidemiologic cohort study.

Methods: We conducted a retrospective cohort study involving residents of British Columbia who had visited an ophthalmologist from 2000 to 2007. Within the cohort, we identified all people who were first-time users of oral bisphosphonates and who were followed to the first inflammatory ocular adverse event, death, termination of insurance or the end of the study period. We defined an inflammatory ocular adverse event as scleritis or uveitis. We used a Cox proportional hazard model to determine the adjusted rate ratios. As a sensitivity analysis, we performed a propensity-score–adjusted analysis.

Results: The cohort comprised 934,147 people, including 10,827 first-time users of bisphosphonates and 923,320 nonusers. The incidence rate among first-time users was 29/10,000 person-years for uveitis and 63/10,000 person-years for scleritis. In contrast, the incidence among people who did not use oral bisphosphonates was 20/10,000 person-years for uveitis and 36/10,000 for scleritis (number needed to harm: 1100 and 370, respectively). First-time users had an elevated risk of uveitis (adjusted relative risk [RR] 1.45, 95% confidence interval [CI] 1.25–1.68) and scleritis (adjusted RR 1.51, 95% CI 1.34–1.68). The rate ratio for the propensity-score–adjusted analysis did not change the results (uveitis: RR 1.50, 95% CI 1.29–1.73; scleritis: RR 1.53, 95% CI 1.39–1.70).

Interpretation: People using oral bisphosphonates for the first time may be at a higher risk of scleritis and uveitis compared to people with no bisphosphonate use. Patients taking bisphosphonates must be familiar with the signs and symptoms of these conditions, so that they can immediately seek assessment by an ophthalmologist.
pensed and the number of days of medication dispensed for all residents of the province. The British Columbia Linked Health Database has been used extensively in health services and pharmacoepidemiologic research.11,12

Study cohort
The cohort included all people who visited an ophthalmologist from January 2000 to December 2007. The date of the first visit to an ophthalmologist was designated as the date of entry to the cohort. We included people who had at least one year of information about prescription drug use in the database.

We defined exposure as the first and only prescription for oral bisphosphonates after entry into the cohort. Because cases of uveitis or scleritis have been reported by first-time users of bisphosphonates,49 we restricted the cohort to only include first-time users, and we excluded people who had received more than one prescription. We defined nonusers as people who had not received a prescription for bisphosphonates during the follow-up period. Cohort members were followed until uveitis or scleritis developed, death, termination of health coverage, or end of the study period, whichever came first.

We obtained ethics approval from the behavioural ethics board at the University of British Columbia.

Case definition
We performed two mutually exclusive analyses with either uveitis or scleritis as the main outcome. We classified cases as people who had a first diagnosis of uveitis or scleritis. We first identified all cases using the first diagnosis of scleritis (International Classification of Diseases, ninth revision [ICD-9] code 379) or uveitis (ICD-9 code 364). We further defined cases of scleritis as those with an ICD-9 code for scleritis and a prescription for an ophthalmic or oral corticosteroid within 30 days of the diagnosis. Although patients who present with scleritis may also be prescribed nonsteroidal anti-inflammatory drugs (NSAIDs), we excluded these drugs from the main analysis because they may be prescribed for many conditions. We performed a sensitivity analysis including patients who had also received a NSAID within 30 days of the diagnosis. We defined cases of uveitis as those who had received a diagnosis of uveitis and were prescribed topical ophthalmic corticosteroids within 30 days of the diagnosis. To ensure no previous diagnoses of scleritis or uveitis had been registered in the database, we checked the period from cohort entry to the date of the outcome and looked for any previous diagnoses of either condition.

Statistical analysis
We used descriptive statistics for demographic information and the distribution of bisphosphonate users and nonusers. We built a Cox proportional hazards model to calculate hazard ratios for each study outcome. We chose a nonparsimonious approach and adjusted for the following covariates: age, sex, calendar time, history of ankylosing spondylitis, diabetes, inflammatory bowel syndrome, systemic lupus erythematosus, multiple sclerosis, psoriasis, rheumatoid arthritis and sarcoidosis. Previous studies have also adjusted for Behçet disease, Reiter syndrome, polychondritis, Wegener granulomatosis and systemic lupus erythematosus.13 However, because

Table 1: Characteristics of included patients, stratified by use of oral bisphosphonate

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. (%)* of patients</th>
<th>First-time bisphosphonate use</th>
<th>No bisphosphonate use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 10 827</td>
<td>n = 923 320</td>
<td></td>
</tr>
<tr>
<td>Scleritis</td>
<td>392 (3.6)</td>
<td>16 305 (1.8)</td>
<td></td>
</tr>
<tr>
<td>Uveitis</td>
<td>185 (1.7)</td>
<td>9 320 (1.0)</td>
<td></td>
</tr>
<tr>
<td>Age cohort entry, yr, mean (SD)</td>
<td>68.7 (12.6)</td>
<td>51.3 (22.3)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>2 414 (22.3)</td>
<td>446 889 (48.4)</td>
<td></td>
</tr>
<tr>
<td>Follow-up, yr, mean (SD)</td>
<td>5.9 (1.9)</td>
<td>4.9 (2.2)</td>
<td></td>
</tr>
<tr>
<td>Sulfur-containing drugs</td>
<td>822 (7.6)</td>
<td>48 013 (5.2)</td>
<td></td>
</tr>
<tr>
<td>Comorbidity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ankylosing spondylitis</td>
<td>32 (0.3)</td>
<td>1 847 (0.2)</td>
<td></td>
</tr>
<tr>
<td>Psoriasis</td>
<td>173 (1.6)</td>
<td>13 850 (1.5)</td>
<td></td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>108 (1.0)</td>
<td>6 463 (0.7)</td>
<td></td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>476 (4.4)</td>
<td>18 466 (2.0)</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>1 602 (14.8)</td>
<td>138 498 (15.1)</td>
<td></td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>152 (1.4)</td>
<td>5 539 (0.6)</td>
<td></td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td>22 (0.2)</td>
<td>923 (0.1)</td>
<td></td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>433 (0.4)</td>
<td>3 693 (0.4)</td>
<td></td>
</tr>
</tbody>
</table>

Note: SD = standard deviation.
*Unless otherwise stated.

Table 2: Crude, adjusted and propensity-adjusted rate ratios for the risk of uveitis and scleritis among first-time users of oral bisphosphonate

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Crude RR (95% CI)</th>
<th>Adjusted* RR (95% CI)</th>
<th>Propensity-adjusted* RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uveitis</td>
<td>1.54 (1.33–1.78)</td>
<td>1.45 (1.25–1.68)</td>
<td>1.50 (1.29–1.73)</td>
</tr>
<tr>
<td>Scleritis</td>
<td>1.85 (1.68–2.05)</td>
<td>1.51 (1.34–1.68)</td>
<td>1.53 (1.39–1.70)</td>
</tr>
</tbody>
</table>

Note: RR = rate ratio.
*Adjusted for age at index, sex, calendar time, use of sulfur-containing drugs, and comorbidities (ankylosing spondylitis, psoriasis, inflammatory bowel disease, rheumatoid arthritis, diabetes, systemic lupus erythematosus, sarcoidosis, multiple sclerosis).
of the small number of people with these conditions in our dataset (72 in total), we excluded them from the analysis. We also adjusted for the use of sulpha-containing medications, because this is the main class of medications that has been shown to increase the risk of inflammatory eye disease. As a sensitivity analysis, we performed a propensity-score–adjusted analysis. We constructed a propensity-score model using the same covariables included in the proportional hazards model. We then constructed a Cox regression model, stratified on the deciles of the propensity score.

Results

From 2000 to 2007, a total of 989,591 people visited an ophthalmologist. Of these, 55,444 people had more than one bisphosphonate prescription; we excluded these people. Thus, we included 10,827 first-time users of bisphosphonates and 923,320 nonusers. Bisphosphonate users were older and more likely to be women (Table 1) compared with nonusers. The incidence rate among bisphosphonate users was 29/10,000 person-years for uveitis and 63/10,000 person-years for scleritis. Among nonusers, the incidence rate was 20/10,000 for uveitis and 36/10,000 for scleritis (number needed to harm: 1100 for uveitis, 370 for scleritis). First-time users of bisphosphonates had an elevated risk of uveitis (adjusted RR 1.45, 95% CI 1.25–1.68) and scleritis (adjusted RR 1.51, 95% CI 1.34–1.68) compared with nonusers (Table 2). The rate ratio for the propensity-score–adjusted analysis did not change the results (uveitis: RR 1.50, 95% CI 1.29–1.73; scleritis: RR 1.53, 95% CI 1.39–1.70).

The results of the sensitivity analysis in which NSAID use was added to the definition for scleritis did not change the results. First-time users of bisphosphonates were still at a higher risk of scleritis compared with nonusers (adjusted RR 1.38, 95% CI 1.26–1.50).

Interpretation

We found that first-time users of bisphosphonates are at an increased risk of scleritis and uveitis. The sensitivity analysis did not change the results for scleritis.

In light of the reported cases of inflammatory ocular adverse events with the use of oral bisphosphonates, these conditions may be more under-reported than other adverse events that are associated with the chronic use of these drugs, mainly atypical fracture and cancer. Only one epidemiologic study has examined the risk of scleritis and uveitis with the use of oral bisphosphonates. French and Margo examined the risk of uveitis and scleritis among a cohort of US veterans with a one-year follow-up period. The relative risk of scleritis and uveitis was reported to be 1.23 among bisphosphonate users but this was not statistically significant. Despite including 35,252 users of bisphosphonates, their study was limited by the small number of events, with only nine cases of uveitis and scleritis reported among first-time users.

The reported cases of scleritis or uveitis with the use of oral bisphosphonates have mainly involved alendronate and risedronate. In most cases, symptoms occurred within days of starting bisphosphonate therapy and resolved upon stopping the drug. Reports of uveitis recurring after re-challenge with pamidronate further corroborate the causal relation, indicating that the use of bisphosphonates as a class may increase the risk of uveitis.

The release of inflammatory mediators is believed to be the possible mechanism for bisphosphonate–induced inflammatory events. Alendronate and risedronate are nitrogen-based aminobisphosphonates and are considered more potent than non-aminobisphosphonates. Aminobisphosphonates have been shown to play a pivotal role in the release of tumour necrosis factor, α-interleukin-6 and cytokines. The surge in the concentration of inflammatory mediators, especially among new users of bisphosphonates, may put some users at a higher risk of scleritis or uveitis.

Limitations

Our study has several limitations. Because of the nature of the data, we could not verify the cases of scleritis or uveitis. Although all the cases were diagnosed by an ophthalmologist, the possibility of misclassification still exists. As with all pharmacoepidemiologic studies that use administrative data, we could only ascertain information about drug dispensing and not drug intake.

Conclusion

The results of our study are consistent with an increase in the risk of scleritis and uveitis with the use of oral bisphosphonates. Uveitis has been associated with major visual morbidity. The cost of vision loss in Canada was estimated to be close to $16 billion in 2007. Bisphosphate-induced uveitis and scleritis are potentially reversible conditions, if there is early intervention by an ophthalmologist. Although the absolute number of cases of uveitis and scleritis in this study was small, the true number of such cases among bisphosphonate users may be clinically important, given that about 5 million prescriptions for bisphosphonates are filled each year in Canada.
The risk of inflammatory ocular adverse events, including scleritis and uveitis, is not highlighted in most package inserts included with oral bisphosphonates. Our study highlights the need for clinicians to inform their patients about the signs and symptoms of scleritis and uveitis, so that prompt treatment may be sought and further complications averted. Patients taking oral bisphosphonates must be familiar with the signs and symptoms of these conditions, so that they can seek immediate assessment by an ophthalmologist.

References